INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (the "Company") on July 15, 2009. The filing discloses the consummation of the initial closing of a private placement offering of convertible promissory notes (the "Bridge Offering") and the entry into material definitive agreements related to this financing.
Key Financial Metrics and Transaction Details
- Capital Raised: $100,000 in principal amount from one accredited investor (Initial Investor).
- Total Offering Size: Up to $500,000 aggregate principal amount.
- Interest Rate: 12% per annum for the Initial Investor (range of 9-12% for the offering), payable in shares of common stock.
- Conversion Price: $0.10 per share of Common Stock.
- Warrant Terms: Detachable warrants issued to purchase shares equal to 100% of the principal divided by the conversion price, with an exercise price of $0.20 per share.
- Placement Agent Fees: Hallmark Investments, Inc. receives a 10% cash fee on gross proceeds and 5-year warrants equal to 10% of the underlying shares.
- Debt Seniority: Notes rank junior to an existing $50,000 SBA Century Bank Line of Credit but senior to all other existing and future indebtedness.
Material Changes and Obligations
The Company has incurred a new direct financial obligation of $100,000. The Maturity Date for the notes is the earlier of one year from issuance or the consummation of a follow-on financing of at least $2,500,000. The Company has agreed to negative covenants limiting the incurrence of additional indebtedness, liens, affiliate transactions, and dividend payments. The filing text does not provide specific revenue, profit, or cash flow metrics for the period, as this report focuses solely on the financing event.
Outlook, Risks, and Contingencies
- Future Closings: The Company expects to consummate additional closings over the next 60 to 90 days to reach the $500,000 target, though no assurances are provided that the remaining amount will be raised.
- Refinancing Trigger: The debt is payable upon a follow-on financing of at least $2.5 million, creating a contingent obligation tied to future capital raising success.
- Regulatory Status: Securities were sold under Section 4(2) of the Securities Act of 1933 as an exemption from registration; they are unregistered and subject to transfer restrictions.
Investor Verification Checklist
- Verify the total amount raised in subsequent closings to determine if the $500,000 target was met.
- Confirm the status of the follow-on financing of at least $2,500,000 to assess if the Maturity Date has been triggered.
- Review the impact of the 12% interest payable in stock on existing shareholder dilution.
- Check compliance with the negative covenants regarding additional indebtedness and affiliate transactions.
- Examine the filed exhibits (10.1 through 10.4) for full legal terms of the notes, warrants, and placement agreement.